RankAlpha logo
Back to Rankings

INBX

Inhibrx BiosciencesF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
Positive clinical readouts or a favorable partnership that improves funding can materially de‑risk the lead programs and drive a multi‑month re‑rating toward the bull target.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Adverse or inconclusive clinical data, partner delays, or the need for dilutive financing would push the stock toward the bear target as risk premia and liquidity pressures increase.
Momentum
26
Value
41
Sentiment
0
Setup hits (3d)
— · Net —
AI TargetsBase $1.92 · Bull $2.88 · Bear $1.15
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-17 • Model: RankAlpha Sentiment AI
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net —
Target $277.50
Why
Momentum26 · Δ7d -7.3
Value41 · Δ7d -0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture. Prioritize risk control and patience.
Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits
Lead driver: Value · See fundamentals
Momentum
26
26% active weight
Current posture
7d trendFlat
Δ7d
-7.3
Δ21d
-10.4
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade

Composite grade F. Momentum 25.6 / Value 41.1 / Sentiment 0.0

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.28B
Beta
-
Shares Out
14.67M
P/E (TTM) · Derived
-9.7
P/S (TTM)
798.66
P/FCF (TTM) · Derived
-10.28
Rev YoY
-100.0%
EPS YoY
-23.4%
Gross Margin
-80.4%
Op Margin
-11002.1%
Net Debt
-$17.21M
Current Ratio
6.46
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology